AEST.MED.INT.HLD.SP.ADR/3 (3FMA) — Tangible Net Worth Ratio
AEST.MED.INT.HLD.SP.ADR/3 (3FMA) has a Tangible Net Worth Ratio of 100.0% as of June 2025. This metric is calculated by deducting intangible assets (€0.00) from net assets (€1.89 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore AEST.MED.INT.HLD.SP.ADR/3 annual equity growth to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
AEST.MED.INT.HLD.SP.ADR/3 Tangible Net Worth Ratio (2023–2024)
This chart shows how AEST.MED.INT.HLD.SP.ADR/3's Tangible Net Worth Ratio has changed across 2 annual periods from 2023 to 2024. As of June 2025, the ratio stands at 100.0%, reflecting net assets of €1.89 Million with intangible assets of €0.00 EUR. For live market cap and overall valuation, see market cap of AEST.MED.INT.HLD.SP.ADR/3.
Annual Tangible Net Worth Ratio for AEST.MED.INT.HLD.SP.ADR/3 (2023–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for AEST.MED.INT.HLD.SP.ADR/3 from 2023 to 2024, covering 2 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore AEST.MED.INT.HLD.SP.ADR/3 capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 61.6% | €9.35 Million | €3.58 Million | €486.22 Million | ▼ -26.8 pp |
| 2023 | 88.5% | €33.63 Million | €3.88 Million | €560.66 Million | — |